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Abstract 
The tyrosine kinase inhibitors sorafenib and imatinib are important in the treatment of 
a range of cancers but adverse effects in some patients necessitate dosage modifications. 
CYP3A4 has a major role in the oxidation of sorafenib to its N-oxide and N-hydroxymethyl 
metabolites and also acts in concert with CYP2C8 to mediate imatinib N-demethylation. 
CYP3A4 expression and function are impaired in patients with advanced liver disease, whereas 
the functions of CYP2C enzymes are relatively preserved. We evaluated the biotransformation 
of sorafenib and imatinib in well-characterized microsomal fractions from 17 control subjects 
and 19 individuals with hepatic cirrhosis of varying severity. The principal findings were that 
liver disease impaired the microsomal oxidation of sorafenib to its major metabolites to 40-
44% of control (P<0.01), whereas the N-demethylation of imatinib was relatively unimpaired. 
The impairments in sorafenib biotransformation were correlated with decreased serum albumin 
concentrations and increased serum bilirubin concentrations in patients with liver disease, but 
not with the overall grade of liver disease according to the Child-Pugh system. In contrast, 
there was no relationship between imatinib N-demethylation and clinicopathologic factors in 
liver disease patients. These findings were accounted for in terms of the differential roles of 
CYPs 3A4 and 2C8 in the intrinsic clearance of the drugs. CYP3A4 has the major role in the 
intrinsic clearance of sorafenib but plays a secondary role to CYP2C8 in the intrinsic clearance 
of imatinib. In agreement with these findings CYP2C protein expression and CYP2C8-
mediated paclitaxel 6-hydroxylation were unimpaired in cirrhotic livers. This information 
could be adapted in individualized approaches such as in vivo CYP3A4 phenotyping to 
optimize sorafenib safety and efficacy in cancer patients with liver dysfunction. 
Keywords:  sorafenib biotransformation, imatinib biotransformation, CYP3A4, CYP2C8, 
hepatic cirrhosis 
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Chemical compounds studied in this article: Sorafenib (PubChem CID: 216239), imatinib 
(PubChem CID: 5291), midazolam (PubChem CID: 4192), paclitaxel (PubChem CID: 
36314), tolbutamide (PubChem CID: 5505), dextromethorphan (PubChem CID: 5360696).  
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1. Introduction 
Tyrosine kinase inhibitors (TKIs) are a recently-developed class of targeted oncology 
drugs that have significantly improved the treatment of patients with a range of tumors. 
Sorafenib and imatinib are two important TKIs that are used in the treatment of liver and renal 
clear cell carcinomas and chronic myelogenous leukemia and gastrointestinal stromal tumors, 
respectively. Sorafenib targets the Raf kinase, vascular endothelial growth factor receptor and 
platelet derived growth factor receptor, while imatinib targets the TKs bcr-abl and c-kit 
(Demetri et al., 2002; Druker et al., 1996; Liu et al., 2006). However, although these agents 
are generally well tolerated, imatinib and sorafenib produce a range of toxicities in certain 
patients, including hypertension, edema or major dermal toxicities such as the hand-foot 
syndrome (Escudier et al., 2007; Ugurel et al., 2003). Such adverse effects may lead to the 
interruption or termination of TKI therapy. 
The aim of personalized medicine is to tailor drug selection and dosage to the individual 
patient. Biotransformation enzymes, especially the hepatic cytochrome P450 (CYP) mixed-
function oxidases, are major factors that influence the rate of drug elimination. Individuals in 
whom CYP oxidation capacity is high may clear drugs rapidly, which can result in treatment 
failure because therapeutic serum concentrations are not maintained, while low CYP oxidation 
may result in drug accumulation and toxicity at standard doses of drugs. Recent studies have 
demonstrated roles for the quantitatively important human hepatic CYP3A and CYP2C 
enzymes in the oxidation of the TKIs sorafenib and imatinib (Dutreix et al., 2004; Ghassabian 
et al., 2012; Lathia et al., 2006; Nebot et al., 2010).  
Liver disease impairs CYP expression directly, which can decrease intrinsic drug 
clearance (CLint), or indirectly as a result of pathophysiological changes that alter hepatic blood 
flow and the perfusion of hepatocytes. Hepatic cirrhosis is a major form of end-stage liver 
disease that is characterized by increased fibrotic infiltration and destruction of the hepatic 
 5 
architecture (Johnson et al., 2010). The obstruction of blood flow promotes portal hypertension 
as well as the development of portacaval shunts, ascites and gastrointestinal bleeding. 
Predictions of the effects of advanced liver disease on the biotransformation of drugs such as 
TKIs are of potential importance in the design of safer dosage regimen in patients (Johnson et 
al., 2010). 
Clinical studies have indicated that the clearance of drugs that are substrates for 
CYP3A4, such as midazolam and erythromycin, is markedly decreased in advanced liver 
disease (Barre et al., 1987; Chalasani et al., 2001). Analogous biochemical studies have shown 
that the oxidative biotransformation of CYP3A4 substrates is impaired because the enzyme is 
down-regulated in liver disease (George et al., 1995; Guengerich and Turvy, 1991). The 
available information on alterations in CYP2C protein expression in patients with liver disease 
is more variable. As summarized by Johnson et al. (2010), the expression of CYP2C protein 
and activity ranged from unchanged in one study to 34-72% of control in two others. However, 
a likely contributing factor to this variation is the use of polyclonal antibodies that were unable 
to discriminate between CYP2C subfamily members. The use of monospecific antibodies and 
selective drug substrates may provide more detailed information on the impact of liver disease 
on individual CYPs 2C. 
The biotransformation of TKIs like sorafenib and imatinib that are metabolized by 
CYP3A could complicate the treatment of cancer patients with hepatic dysfunction. 
Accordingly, the present study evaluated the biotransformation of these TKIs in well-
characterized hepatic microsomal fractions from patients with cirrhotic liver disease, compared 
with control. The principal finding to emerge was that the dysregulation of CYP3A4 in 
cirrhosis markedly decreased sorafenib biotransformation, whereas imatinib oxidation, which 
also involves a significant contribution from the CYP2C8 enzyme, was relatively preserved. 
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These findings may assist the design of dosage modification approaches in patients with liver 
disease and who receive TKIs that have a high dependence on CYP3A4 for clearance.  
 7 
2. Materials and Methods 
2.1 Drugs and Chemicals 
Sorafenib (4-[4-([4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino)phenoxy]-N-
methylpyridine-2-carboxamide) and its N-oxide and N-hydroxymethyl metabolites were 
synthesized as described previously (Gillani et al., 2015). Imatinib mesylate ((4-[(4-
methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-
yl)amino]phenyl]benzamide)), N-desmethylimatinib and imatinib-d8 (internal standard) were 
gifts from Novartis (Basel, Switzerland). Midazolam, dextromethorphan, dextrorphan, and all 
biochemicals were obtained from Sigma-Aldrich (Castle Hill, NSW, Australia). Sorafenib-
methyl-d3 and 6-hydroxypaclitaxel were purchased from Toronto Research Chemicals (North 
York, ON, Canada) and 1’-hydroxymidazolam was from Cerilliant (Round Rock, TX, USA). 
HPLC grade solvents were from LabScan (Lomb Scientific, Taren Point, NSW, Australia), and 
analytical grade reagents were from Ajax Chemicals (Sydney, NSW, Australia).  
 
2.2 Liver donors and preparation of microsomal fractions 
Experiments with human liver microsomes were approved by ethics committees of the 
Western Sydney Area Health Service and the University of Sydney, according to the 
Declaration of Helsinki. Liver tissue from 36 individual donors was obtained through the 
Queensland and Australian Liver Transplant Programs (Princess Alexandria Hospital, 
Brisbane, Queensland, and Royal Prince Alfred Hospital, Sydney, NSW, Australia, 
respectively). “Control” human liver was obtained as excess tissue during transplantation or as 
biopsies from the normal margin during resection of liver tumours. Cirrhotic tissue was 
obtained from individuals in whom the presence of ascites, hepatic encephalopathy and sepsis 
was recorded by the attending physician. The severity of liver disease was graded according to 
the Child-Pugh system which is calculated from the clinical assessment of ascites, 
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encephalopathy, serum albumin and bilirubin concentrations, and prothrombin time. Each 
variable is graded between 1 and 3 based on the extent of impairment. The total Child–Pugh 
score ranges from 5 to 15, where 5 indicates that there is no hepatic decompensation and where 
15 indicates severe liver failure (Christensen et al., 1984). The nutritional status of patients in 
the present study was assessed as normal, impaired or cachectic, based on the extent of muscle 
bulk and subcutaneous fat. Drug histories were collected where information was available. 
In patients, venous blood samples were withdrawn after an overnight fast and used to 
determine serum bilirubin and albumin concentrations and prothrombin times. Blood was 
centrifuged and stored at -70°C until subjected to automated analysis (Department of Clinical 
Chemistry, Westmead Hospital, Westmead, NSW, Australia). 
Liver tissue was obtained from the superior surface of the right lobe within 0.25 h of 
surgical removal, perfused with cold Viaspan solution (DuPont, Wilmington, DE, USA), snap 
frozen in liquid nitrogen and stored at -70°C. Liver microsomes were prepared by 
ultracentrifugation and stored at -70°C in potassium phosphate buffer (0.05 M, pH 7.4, 
containing 1 mM EDTA and 20% glycerol; Murray et al., 1985). Microsomal protein content 
was determined as described previously (Marcus et al., 1985).  
 
2.3 Drug biotransformation by human liver microsomes 
In all assays of drug biotransformation the linearity of product formation in incubations 
was established in relation to microsomal protein, substrate concentration and incubation time. 
Substrate concentrations were 2-11-fold of reported Km, with the exception of the low-affinity 
substrate tolbutamide, which was studied around the Km. To ensure enzyme saturation the 
substrate utilization was limited to <15% in all cases.  
Microsomal sorafenib biotranformation was determined as described previously 
(Ghassabian et al., 2012). Briefly, incubations (75 µg microsomal protein, 75 µM sorafenib) 
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in 0.1 M potassium phosphate buffer (pH 7.4, 0.25 mL) at 37ºC were initiated using NADPH 
(1 mM). Reactions were terminated after 20 min with cold acetonitrile (0.5 mL), the precipitate 
was removed by centrifugation and the supernatant was dried under a stream of nitrogen gas; 
the internal standard was sorafenib-methyl-d3. Sorafenib and its metabolites were quantified 
on a Thermo Scientific TSQ Quantum Access Max liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) system using electrospray ionization (positive ion mode; San Jose, 
CA, USA) with separation on a Waters XTerra MS C18 3.5µ column (150 x 2.1 mm I.D.; 
Waters, Rydalmere, NSW, Australia).  
Microsomal imatinib biotranformation was determined as described previously (Nebot 
et al., 2010). Briefly, incubations (150 µg microsomal protein, 80 µM imatinib) in 0.1 M 
potassium phosphate buffer (pH 7.4, 0.2 mL) at 37ºC were initiated with NADPH (1 mM). 
Reactions were terminated after 10 min with 5% trifluoroacetic acid (5 µL) and applied to 
Varian Bond Elut Plexa solid-phase extraction cartridges (1 mL). Cartridges were eluted with 
methanol (3 x 1.25 mL aliquots) which was then evaporated to dryness; the internal standard 
was imatinib-d8. Imatinib and N-desmethylimatinib were quantified on a Finnigan MAT TSQ 
7000 LC-MS/MS system using electrospray ionization (positive ion mode; San Jose, CA, USA) 
with separation on an Altima C18 5µ column (150 x 2.1 mm I.D.; Alltech Associates, Castle 
Hill, NSW, Australia).  
CYP3A-mediated midazolam 1’-hydroxylation was determined as described 
previously (Ghassabian et al., 2009). Incubations (100 µg microsomal protein, 5 µM 
midazolam) in 0.1 M potassium phosphate buffer (pH 7.4, 0.5 mL) at 37°C were initiated by 
NADPH (1 mM). Reactions were terminated after 5 min with cold 0.1% formic acid (1.5 mL) 
and applied to Bond Elut C18 SPE cartridges (Agilent Technologies, Mulgrave, VIC, 
Australia). After washing with ammonium acetate (10 mM, 1 mL) cartridges were eluted with 
methanol (2 x 1 mL); the internal standard was diazepam. Midazolam and its 1’-hydroxy-
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metabolite were separated on a Finnigan MAT TSQ 7000 LC-MS/MS system using 
electrospray ionization (positive ion mode) with separation on an Altima C18 5µ column (150 
x 2.1 mm I.D.).  
CYP2C8-mediated paclitaxel 6α-hydroxylation activity was determined as described 
previously (Vaclavikova et al., 2003). Incubations (150 µg microsomal protein, 25 µM 
paclitaxel) in 0.1 M potassium phosphate buffer (pH 7.4, 0.5 mL) at 37°C were initiated with 
NADPH (1 mM). Reactions were terminated after 90 min with cold acetonitrile (1 mL) and the 
organic layer was evaporated under nitrogen; the internal standard was timolol. After 
reconstitution with mobile phase (20 mM ammonium acetate: acetonitrile: methanol, 5:3:2; 0.1 
mL) extracts were subjected to HPLC analysis on a Finepak SIL C18-5 column (15 cm x 4.6 
mm I.D.; JASCO, Meadowbank, NSW, Australia) with UV detection (227 nm).  
CYP2C9-mediated tolbutamide methylhydroxylation activity was determined as 
described previously (Murray et al., 1994). Incubations (200 µg microsomal protein, 150 µM 
tolbutamide) in 0.1 M potassium phosphate buffer (pH 7.4, 0.5 mL) at 37°C were initiated with 
NADPH (1 mM). Reactions were terminated after 15 min with cold HCl (7.5 M, 20 µL), 
extracted with diethyl ether (2 x 1 mL) and the organic layer was evaporated under nitrogen; 
the internal standard was chlorpropamide. Extracts were reconstituted with mobile phase 
(acetonitrile: 0.05% phosphoric acid, 3:7; 0.4 mL) and subjected to HPLC analysis on an 
Inertsil ODS-2 column (5 µ 15 cm x 4.6 mm I.D.; GL Science, Tokyo, Japan) with UV 
detection (230 nm).  
CYP2D6-mediated dextromethorphan O-demethylation activity was determined as 
described previously (Ghassabian et al., 2009). Incubations (150 µg microsomal protein, 16 
μM dextromethorphan) in potassium phosphate buffer (0.1 M, pH 7.4) at 37°C were initiated 
with NADPH (1 mM). Reactions were terminated after 30 min with ice-cold buffer and loaded 
onto Oasis HLB solid-phase cartridges (Waters Associates, Rydalmere, NSW, Australia). 
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Cartridges were washed with 10% aqueous methanol (2 x 1 mL) and then eluted with methanol 
(2 x 1 mL); the internal standard was phenacetin. Dextromethorphan and dextrorphan were 
separated on a Finnigan MAT TSQ 7000 LC-MS/MS system using electrospray ionization 
(positive ion mode) with separation on an Altima C18 5µ column (150 x 2.1 mm I.D.).  
 
2.4 Immunoquantification of microsomal proteins 
Hepatic microsomal protein (10 µg for CYP3A4, 5 µg for CYP3A5, 10 µg for CYP2C 
and 25 µg protein for CYP2D6) was resolved on 10% sodium dodecyl sulfate-polyacrylamide 
gels (2 h at 120 V), transferred electrophoretically to Protran nitrocellulose (Schleicher and 
Schuell, Dassel, Germany) and then subjected to Western immunoblot analysis as described 
previously (Stupans et al., 2001). Monospecific rabbit antibodies directed against peptides that 
corresponded to the C-terminal regions of human CYP2C8, CYP2D6, CYP3A4 and CYP3A5 
were prepared as described by Edwards et al. (1998). Immunoreactive proteins were detected 
by enhanced chemiluminescence (GE Healthcare, Chalfont St. Giles, UK) on Hyperfilm-ECL 
(Amersham, Little Chalfont, UK) and the resultant signals were analyzed by densitometry 
(Bio-Rad, Richmond, CA). Signal intensity was linear under these conditions. 
 
2.5 Statistical analyses 
Data are expressed throughout as means ± S.E.M. Differences between activities in control and 
liver disease samples were detected using the unpaired two-tailed Student’s t-test after log 
transformation (Statview; Abacus concepts, Berkeley, CA, USA). P values < 0.05 were 





3.1 Clinicopathologic factors and drug histories in patients who donated liver tissue 
Of the 36 patients who provided liver tissue seventeen were classed as controls because 
there was no evidence of liver disease, as defined by nutritional status, ascites or hepatic 
encephalopathy; nineteen patients had liver disease of varying severity (Table 1). Five of the 
liver disease patients were diagnosed with autoimmune chronic active hepatitis, four had 
primary biliary cirrhosis and three had primary biliary sclerosing cholangitis. Of the remaining 
liver disease patients one each had alcoholic liver disease, 1-antitrypsin deficiency, idiopathic 
cirrhosis, Budd-Chiari syndrome, hepatitis C and biliary atresia, while a further patient was 
diagnosed with coincident alcoholic liver disease and 1-antitrypsin deficiency. Nutritional 
status was impaired in four of the liver disease patients and seven had cachexia. In three patients 
mild ascites was present, moderate ascites was present in another and four patients exhibited 
severe ascites. Three patients exhibited severe hepatic encephalopathy while in another hepatic 
encephalopathy was less pronounced. One patient presented with sepsis and another had a 
secondary diagnosis of diabetes mellitus. Taken together, eleven patients were assessed as 
having the most severe liver dysfunction in cirrhosis (Child-Pugh class C), seven were Child-
Pugh class B and one was Child-Pugh class A. 
All of the liver disease patients received concurrent medications (Table 1). The most 
commonly prescribed agents were diuretics (spironolactone and frusemide), anti-infectives 
(norfloxacin, cefotaxime, ciprofloxacin and rifampicin), H2-receptor antagonists (ranitidine, 
omeprazole and cimetidine), -receptor antagonists (propranolol and atenolol), analgesics 
(pethidine, paracetamol and codeine) and glucucorticoids (prednisone and hydrocortisone). 
Some patients also received oxazepam, sucralfate, insulin and thyroxine. 
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Drug histories were also available for eight of the control liver donors. Drugs used in 
these patients included cephalothin, metronidazole, -methyldopa, colloidal bismuth 
subcitrate, sucralfate, oxazepam and simvastatin (one instance each; not shown). 
Information from liver function tests was available for all of the patients with liver 
disease and eight of the controls. As shown in Fig 1 serum albumin concentrations were 
decreased in donors with liver disease (29±1 mg/mL, range 23-41 mg/mL, compared to 42±1 
mg/mL in control; p<0.001; the normal range is ~36-55 mg/mL). Serum bilirubin 
concentrations were increased in cirrhotic patients (137±32 µM, range 18-488 µM, compared 
to normal concentrations of ≤20 µM; p<0.05) and prothrombin time was prolonged (27±3 sec, 
range 12-60 sec, compared to normal ≤14 sec; p<0.05). 
 
 
Figure 1:Serum albumin and bilirubin concentrations and prothrombin times in patients with 
liver disease (LD) compared with control (CTL) subjects. Different from control: *P<0.05, 





Clinicopathological characteristics of liver disease patientsa,b 
          
Patient diagnosis nutritional ascites hepatic Child-Pugh Drugs  
(arbitrary  status (score) encephalopathy grade 
number)  (score)c  (score)  
         
1 alcoholic liver disease, 1-antitrypsin deficiency 3 3 0 C NOR, RAN, OXA 
2 1-antitrypsin deficiency 2 2 0 B OXA, SPI, OME 
3 idiopathic cirrhosis without cholestasis 3 0 0 B SPI, SUC 
4 autoimmune chronic active hepatitis 1 2 0 C SPI, PRE 
5 autoimmune chronic active hepatitis 1 0 2 C PRE 
6 Budd Chiari syndrome 3 1 0 C RAN, CEF, PRO, PET, HYD 
7 autoimmune chronic active hepatitisd 3 3 0 C RAN, PRE, INS 
8 alcoholic liver disease 1 0 0 B SPI, PRO, FRU, CIM 
9 autoimmune chronic active hepatitis 1 0 0 B NOR, SPI, PRE, PRO 
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10 autoimmune chronic active hepatitis 1 0 1 A PRE 
11 hepatitis C 2 1 0 C SPI, CIP 
12 primary biliary cirrhosis 2 0 0 C NOR, SPI 
13 primary sclerosing cholangitis 1 0 0 B CIP 
14 primary biliary cirrhosis 3 0 0 C SPI, ATE 
15 biliary atresia and idiopathic intrahepatic cholestasis 3 0 0 B SPI, RIF 
16 primary sclerosing cholangitise 2 1 0 C CEF 
17 primary biliary cirrhosis 1 0 2 C RAN, SPI, FRU 
18 primary sclerosing cholangitis 3 0 0 B RAN, PAR, COD 
19 primary biliary cirrhosisf 1 0 2 C SPI, THY 
                 
Demographic factors: aage range 0-66 years, bM:F 7:12. 
cscore: nutritional status: 1 normal, 2 impaired, 3 cachexia; ascites: 0 nil, 1 mild, 2 moderate, 3 severe; hepatic encephalopathy: 0 (none)-2; 
Overall Child-Pugh grade A, B or C. 
dCo-diagnosis: diabetes mellitus.  
eSepsis. 
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fSmoker (>5 cigarettes/day). 
Concurrent drugs: NOR, norfloxacin; RAN, ranitidine; OXA, oxazepam; SPI, spironolactone; OME, omeprazole; SUC, sucralfate; PRE, 
prednisone; CEF, cefotaxime; PRO, propranolol; PET, pethidine; HYD, hydrocortisone; INS, insulin; FRU, frusemide; CIM, cimetidine; CIP, 




3.2 Impact of liver disease on TKI biotransformation and CYP expression 
 
Figure 2: (A) Biotransformation of sorafenib to its N-oxide and N-hydroxymethyl 
metabolites, (B) rates of sorafenib N-oxide and N-hydroxymethylsorafenib formation in 
microsomal fractions from control (CTL) and liver disease (LD) patients. Different from 
control: **P<0.01. Horizontal bars indicate data means. 
 
Sorafenib was oxidized to two major metabolites in human liver microsomes: sorafenib 
N-oxide and N-hydroxymethylsorafenib (Fig 2A). Sorafenib N-oxide formation was lower in 
microsomes from patients with liver disease to 44±8% of that in control liver fractions (64±12 
pmol/mg protein/min; range 1-187 pmol/mg protein/min, versus 146±24 pmol/mg protein/min 
in control, range 7-312 pmol/mg protein/min; P<0.01; Fig 2B). Similarly, N-hydroxymethyl 
sorafenib formation was lower in microsomes from patients with liver disease to 40±10% of 
control (33±9 pmol/mg protein/min, range 0-118 pmol/mg protein/min versus 83±14 pmol/mg 
protein/min in control, range 0-177 pmol/mg protein/min; P<0.01; Fig 2B). Because CYP3A 
has a major role in the biotransformation of sorafenib we also measured CYP3A-dependent 
A B
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midazolam 1’-hydroxylation in microsomal fractions. The activity was lower in microsomes 
from patients with liver disease to 61±8% of control (0.22±0.03 nmol/mg protein/min 
compared with 0.36±0.04 nmol/mg protein/min in control; p<0.01; Fig 3A). In accord with 
these findings, CYP3A4 protein expression was lower in liver disease fractions (47±13% of 




Figure 3: Rates of (A) CYP3A-mediated midazolam 1’-hydroxylation (B) CYP2C8-
mediated paclitaxel 6-hydroxylation (C) CYP2C9-mediated tolbutamide 
methylhydroxylation and (D) CYP2D6-mediated dextromethorphan O-demethylation in 
control (CTL) and liver disease (LD) microsomal fractions. Different from control: **P<0.01 




In this study we also assessed whether liver disease altered the microsomal oxidation 
of another major TKI imatinib. However, in contrast to sorafenib biotransformation, imatinib 
N-demethylation was not significantly lower in microsomal fractions from patients with 
hepatic cirrhosis (18±3 pmol/mg protein/min; range 6.8-63 pmol/mg protein/min versus 22±3 
pmol/mg protein/min in control; range 6.3-35 pmol/mg protein/min; Fig 5). Because both 
CYP3A and CYP2C8 have been shown to participate in imatinib N-demethylation we 
measured CYP2C8-mediated paclitaxel 6-hydroxylation in microsomal fractions. It was 
found that liver disease did not alter paclitaxel 6-hydroxylation significantly (37±7 pmol/mg 
protein/min; range 0-89 pmol/mg protein/min in liver disease versus 37±5 pmol/mg 
protein/min; range 10-68 pmol/mg protein/min in control; Fig 3B). To further evaluate the 
impact of liver disease on CYPs 2C we measured the activity of the closely related CYP2C9, 
as reflected by tolbutamide methylhydroxylation. The activity was also unchanged in samples 
from patients with liver disease (0.22±0.03 nmol/mg protein/min; range 0-0.51 nmol/mg 
protein/min in liver disease versus 0.25±0.03 nmol/mg protein/min; range 0.04-0.41 nmol/mg 
protein/min in control; Fig 3C). In comparison, CYP2D6-mediated dextromethorphan O-
demethylation was unchanged in microsomes from patients with liver disease (53±11 pmol/mg 
protein/min; range 0-155 pmol/mg protein/min versus 54±19 pmol/mg protein/min; range 0-
231 pmol/mg protein/min in control; Fig 3D). In accordance with these findings total 
immunoreactive CYP2C and CYP2D6 proteins were not significantly lower in cirrhotic liver 
than in control liver (Fig 4). These findings suggest that, of the CYPs evaluated in the present 
study, CYP3A4 is selectively decreased in liver disease, and that this leads to different effects 
on the oxidative biotransformation of the TKIs sorafenib and imatinib. CYPs 2C and CYP2D6 






Figure 4: Immunoreactive CYP3A4, CYP3A5, CYP2C and CYP2D6 expression in 
microsomal fractions from control (CTL) subjects and patients with liver disease (LD). 
Immunoblots in nine representative CTL and LD microsomal fractions are shown. Different 





Figure 5:  Biotransformation of imatinib to its N-desmethyl metabolite in microsomal 
fractions from control (CTL) and liver disease (LD) patients. Horizontal bars indicate data 
means. 
3.3 Relationship of liver dysfunction to CYP biotransformation capacity 
The relationships between clinicopathological factors in patients that relate to liver 
function, and the formation of major metabolites of sorafenib and imatinib were assessed. As 
shown in Figure 6A the formation of both sorafenib N-oxide and N-hydroxymethylsorafenib 
was positively correlated with serum albumin (r=0.68 in both cases, P<0.001) and negatively 
correlated with serum bilirubin concentrations (r=-0.57 and -0.58, respectively, P<0.01). N-
Hydroxymethylsorafenib formation was also negatively correlated to prothrombin time (r=-
0.44, p<0.05), whereas the relationship with sorafenib N-oxide formation was not significant 
(r=-0.34). In contrast, imatinib N-demethylation was inversely correlated with serum bilirubin 
concentrations (r=-0.42, P<0.05) but not serum albumin concentrations or prothrombin time 
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(not shown). We assessed whether the extent of impairment in sorafenib biotransformation was 
related to the Child-Pugh grade of the donor patients. However, as shown in Fig 6B, there was 
no clear relationship between the severity of liver disease, according to the Child-Pugh system, 




Figure 6: (A) Regression analysis of the relationships between sorafenib N-oxide and N-
hydroxymethylsorafenib formation and serum albumin concentrations, serum bilirubin 
concentrations and prothrombin times in control (squares) and liver disease (circles) patients. 
(B) Sorafenib metabolite formation (sum of N-oxide and N-hydroxymethyl) metabolites in 
microsomal fractions from patients with liver disease of varying Child-Pugh grade. The 
patient samples of each Child-Pugh grade that are above and below the mean value 






TKIs such as sorafenib and imatinib are well tolerated in most subjects but some 
patients experience toxicity that necessitate dose reduction or cessation. Knowledge of 
clearance pathways is required for the development of personalized approaches to optimize 
therapy based on drug pharmacokinetics. Recent work has established that CYP3A4 and 
CYP3A5 are important catalysts in the formation of major sorafenib metabolites and that these 
enzymes act in conjunction with CYP2C8 in the N-demethylation of imatinib. 
To avoid drug toxicity careful dosing is important in patients with liver disease because 
pathophysiological changes directly alter the clearance of drugs (Franz et al., 2013). Decreased 
functional liver mass, decreased CYP biotransformation enzymes, altered plasma protein 
binding and altered hepatic blood flow each exert differential effects on drug clearance 
(Johnson et al., 2010); only the unbound fraction of drug is cleared. For drugs that are highly 
extracted by the liver, altered liver blood flow has the major effect on rates of systemic 
clearance, whereas low extraction drugs are more dependent on rates of intrinsic hepatic 
clearance. Sorafenib and imatinib are low hepatic extraction drugs that are highly protein bound 
(~99% and 95%, respectively). Accordingly, liver disease is likely to influence their clearance 
by decreasing intrinsic clearance and possibly also by decreasing the synthesis of albumin, 
which could modulate unbound drug concentrations.  
In liver disease the impairment of systemic drug clearance is related to the particular 
drug. The clearances of CYP3A substrates, midazolam, nifedipine and erythromycin are lower 
in patients with severe liver disease (Barre et al., 1987; Chalasani et al., 2001; Ene and Roberts, 
1987). Thus, Johnson et al. (2010) proposed that an understanding of the role of CYP3A and 
other biotransformation enzymes in clearance is essential to begin to design modified dosage 
regimen. In the present study CYP3A4-dependent oxidation of the TKI sorafenib was lower in 
microsomes from patients with chronic liver disease, consistent with the decline in CYP3A4 
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expression and function in these fractions. In contrast, imatinib N-demethylation was relatively 
preserved in microsomes from patients with severe liver disease. Because CYP2C8 is an 
important contributor to the activity we evaluated this finding further and noted that CYP2C8-
mediated paclitaxel 6-hydroxylation and CYP2C protein were not impaired in the fractions 
from patients with liver disease. This is consistent with clinical reports that the impact of liver 
disease on the clearance of CYP2C drug substrates is less pronounced than on the clearance of 
CYP3A substrate drugs (Villeneuve and Pichette, 2004; Johnson et al., 2010). More recently, 
CYP2C8 expression and function was also found to be essentially unaltered during the 
progression of human non-alcoholic fatty liver disease, which is a form of liver injury that can 
precede the development of more advanced disease (Fisher et al., 2009; Rong et al., 2010).  
Because sorafenib and imatinib are low hepatic extraction drugs we considered the roles 
of CYPs in their CLint. From measurements in cDNA-expressed CYPs the catalytic efficiencies 
of CYP3A4 and CYP3A5 in sorafenib N-oxidation were found previously to be 9.4 and 0.74 
pmol/pmol CYP/h/µM, respectively, and 4.5 and 0.8 pmol/pmol CYP/h/µM, respectively, in 
N-hydroxymethylsorafenib formation (Ghassabian et al., 2012). In the case of imatinib N-
demethylation the catalytic efficiencies of CYP2C8, CYP3A4 and CYP3A5 were reported to 
be 17.5, 1.2 and 1.0 pmol/pmol CYP/h/µM, respectively (Nebot et al., 2010). Thus, the relative 
contribution of CYP2C8 to imatinib N-demethylation is ~15-fold of that of CYP3A4. Recent 
estimates of CYP3A4 content in human liver are in the range 0-350 pmol/mg microsomal 
protein (Huang et al., 2004; Naraharisetti et al., 2010) while CYP2C8 is in the range 0-90 
pmol/mg microsomal protein (Bahadur et al., 2002; Naraharisetti et al., 2010; Rodriguez-
Antona et al., 2008). Thus, the mean expression of CYP2C8 protein is ~0.25-fold of that of 
CYP3A4. CYP3A5 is absent from many livers because an intron polymorphism introduces an 
mRNA splicing defect that prevents the translation of CYP3A5 protein (Huang et al., 2004; 
Lin et al., 2002). Adaptation of this information suggests that the relative contribution of 
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CYP2C8 to the CLint of imatinib is ~3.6-fold that of CYP3A4 (17.5/1.2 x 0.25). Taken together 
these findings suggest that the major role of CYP3A4 in the CLint of sorafenib is responsible 
for the loss of oxidation capacity. In contrast, CYP2C8 activity was not markedly lower in liver 
disease, which could facilitate the relative preservation of imatinib N-demethylation. 
The pharmacokinetic behaviour of sorafenib and imatinib is complex and exhibits wide 
inter-individual variation (Minami et al., 2008; Strumberg et al., 2007; Widemann et al., 2012); 
this complicates dose determination. The area under the serum concentration versus time curve 
(AUC) values for both sorafenib and imatinib were altered over time in patients who received 
fixed doses (Boudou-Rouquette et al., 2012; Judson et al., 2005). Compared to AUC data after 
one day of treatment, both drugs accumulated at steady state and showed increased AUC values 
that then declined after prolonged treatment (Boudou-Rouquette et al., 2012; Eechoute et al., 
2012; Furuse et al., 2008; Peng et al., 2004).  
There have been clinical reports that the pharmacokinetics of sorafenib may be 
complicated in some patients with liver disease, which could have consequences for safety 
(Arrondeau et al., 2012; Abou alfa et al., 2006; Fukudo et al., 2014; Miller et al., 2009; 
Shimada et al., 2015). Earlier studies reported no differences in pharmacokinetics in patients 
with mild-moderate liver dysfunction (Child-Pugh grade A or B), although inter-patient 
variation was high (Abou alfa et al., 2006). However, although single dose sorafenib produced 
similar AUC values in patients with a range of liver disease severities, toxicity was observed 
in patient cohorts with more severe liver dysfunction, even at lower doses (Miller et al., 2009). 
To date, there have been few studies of sorafenib pharmacokinetics in patients with the highest 
grade of liver dysfunction (Child-Pugh grade C disease) (Fukudo et al., 2014; Kane et al., 
2009). Indeed, such studies are impractical in patients with severe liver dysfunction who 
require significant dose reductions to tolerate the drug (some can tolerate only 200 mg every 
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third day compared with 400 mg twice daily in patients with normal liver function; Miller et 
al., 2009).  
The pharmacokinetics and tolerability of imatinib appear to be unchanged in patients 
with impaired liver function. A study of two patients with GIST with impaired liver function 
reported normal responses to standard doses of imatinib over 3-4 months of therapy with no 
increase in toxicity (Bauer et al., 2005). Two larger studies reported that imatinib was effective 
in patients with concurrent liver dysfunction and CML (Tong et al., 2010) or a range of 
malignancies (Ramanathan et al., 2008). Moreover, despite large inter-patient variability, the 
plasma pharmacokinetics and urinary excretion of imatinib did not differ between patients with 
normal function and liver dysfunction (Ramanathan et al., 2008). The current consensus 
appears to be that imatinib can be safely administered at the recommended dose provided liver 
function is closely monitored (Judson, 2008; Eckel et al., 2005). 
The microsomal fractions used in this study were prepared from “control” liver donated 
by subjects without hepatic dysfunction and 19 individuals with impaired liver function, 18 of 
whom were either Child-Pugh grade B or C. Regulatory agencies have prepared guidance 
documents for drug evaluations in patients with impaired liver function that relate drug 
clearance to the Child–Pugh grade and suggest that pharmacokinetic studies are warranted if 
biotransformation represents ≥ 20% of overall elimination or if the drugs have narrow 
therapeutic indices (USFDA, 2003). There are several limitations to the Child-Pugh system, 
which was not originally devised as a tool to assess drug metabolizing capacity. It performs 
best in patients with decompensated end-stage severe liver disease but otherwise lacks 
discriminatory power. In addition, the constituent variables are influenced by factors other than 
liver dysfunction (Zgheib and Branch, 2017). Whether serum concentrations of albumin or 
bilirubin, or other endogenous parameters, such as serum cholesterol, may be more reliable 
indicators of altered TKI drug clearance in liver dysfunction remains to be fully explored, but 
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there is evidence that they may have some utility. As mentioned, sorafenib is highly bound to 
serum albumin and a decrease in hepatic albumin production has been found to alter sorafenib 
clearance in cancer patients (Tod et al., 2011). Furthermore, Miller et al., (2009) found that 
higher bilirubin concentrations were associated with lower AUCs for sorafenib N-oxide in 
patient cohorts with diminished liver function. However, in the present study microsomal TKI 
biotransformation was only partially correlated with serum albumin and bilirubin 
concentrations. Taken together, it is probably unlikely that such parameters will be useful for 
dose personalization in patients with liver disease because they are insensitive indicators of 
drug oxidation capacity. Instead, the present findings suggest that longitudinal monitoring of 
serum levels of sorafenib (Shimada et al., 2015) or in vivo CYP3A4 phenotyping using the 
erythromycin breath test or midazolam clearance, might better predict clearance in individual 
patients (Ghassabian et al., 2009; Ramanathan et al., 2008).  
 
5. Conclusion 
In the present study clinical parameters relating to liver function were correlated with 
the biotransformation of sorafenib, as well as to the CYP3A substrate midazolam, but not to 
the biotransformation of imatinib. These findings were attributed to the differential effects of 
liver disease on CYP3A4 and CYP2C8 that have major roles in the CLint of sorafenib and 
imatinib, respectively. The overall Child–Pugh grade, which has been used to determine dosage 
modifications for potentially toxic drugs in patients with liver disease, was not closely related 
to CYP3A function or sorafenib biotransformation. The lack of discriminatory power and 
specificity of the Child-Pugh system are limitations to its use in the assessment of drug 
clearance by the liver (Zgheib and Branch, 2017). Accordingly, more direct measures of 
sorafenib elimination in patients, such as therapeutic monitoring or in vivo phenotyping for 
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CYP3A4 could be warranted to enable dose determination protocols to be developed for some 
TKI drugs (Ghassabian et al., 2009; Ramanathan et al., 2008). 
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